electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
Current Portion of Long-Term Debt
electroCore, Inc.
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Current Portion of Long-Term Debt
$1.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
21%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Current Portion of Long-Term Debt
$1.7B
|
CAGR 3-Years
85%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Stryker Corp
NYSE:SYK
|
Current Portion of Long-Term Debt
$1.4B
|
CAGR 3-Years
486%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Current Portion of Long-Term Debt
$1.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
3%
|
CAGR 10-Years
39%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
You don't have any saved screeners yet